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Introduction {#sec1}
============

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a positive-sense single-stranded RNA virus that was first isolated in Wuhan, China in December 2019 from a cluster of acute respiratory illness cases ([@bib50]). SARS-CoV-2 is related closely to other highly pathogenic betacoronoaviruses that emerged this century---SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV). SARS-CoV-2 is the cause of the coronavirus disease 2019 (COVID-19) pandemic that has infected millions of people worldwide, resulted in hundreds of thousands of deaths, and engendered severe and destabilizing global economic hardship. COVID-19 is characterized by fever, cough, and shortness of breath that can progress rapidly to respiratory and cardiac failure requiring mechanical ventilation ([@bib15]). The elderly, immunocompromised, and those with co-morbid metabolic, pulmonary, and cardiac conditions are at greater risk of death from COVID-19 ([@bib49]). Most human infections occur after respiratory droplet exposure, with community transmission in asymptomatic or pauci-symptomatic individuals contributing to local and global spread ([@bib11], [@bib25]).

Coronaviruses are spherical virions in which the viral spike (S) protein forms a characteristic crown on the virion surface. Three additional viral structural proteins (envelope \[E\], membrane \[M\], and nucleocapsid \[N\]) together with a lipid membrane and ∼25--31 kilobase viral genome comprise the virion. The S protein exists on virions as homotrimeric spikes that promote coronavirus entry into cells via attachment and membrane fusion. Both SARS-CoV and SARS-CoV-2 S proteins engage the human angiotensin-converting enzyme 2 (hACE2) as a cellular receptor for entry and infection ([@bib16]). After receptor engagement, SARS-CoV-2 S protein is enzymatically processed by a plasma membrane-associated serine protease, TMPRSS2, which is essential for efficient fusion and release of the virus contents into the host cell cytosol ([@bib16], [@bib27]).

The rapid emergence of this highly pathogenic and readily transmissible SARS-CoV-2 has created an urgent need for the immediate development and deployment of antiviral agents and protective vaccines. Remdesivir, a direct-acting antiviral polymerase inhibitor with activity against coronaviruses in mice ([@bib38]), was recently approved in the United States under an emergency order for human use against SARS-CoV-2 ([@bib23]), although an initial randomized, double-blinded trial in China did not show substantive benefit ([@bib46]). Several other repurposed drugs and antibody product-based agents are under evaluation in human studies ([@bib37]), Additionally, vaccine trials in humans with mRNA, DNA, and viral-vectored platforms have been initiated without published efficacy data in small or large animal models ([@bib2]). The development of a high-throughput small animal model of SARS-CoV-2 infection could expedite testing of drugs and vaccines and enable down-selection before more costly evaluation in non-human primate and human clinical trials. Indeed, despite much anticipation ([@bib19]), neutralizing monoclonal antibodies against SARS-CoV-2 ([@bib45]) have not yet been demonstrated to have protective activity in any preclinical model.

Reportedly, laboratory strains of mice are not readily infected by SARS-CoV-2 because hACE2 supports SARS-CoV-2 binding but mouse ACE2 does not ([@bib24], [@bib44]). Although transgenic mice expressing hACE2 (hACE2-Tg) were developed for SARS-CoV research ([@bib28], [@bib32]) and develop interstitial pneumonia after SARS-CoV-2 infection ([@bib3]), they are not widely available for high-throughput drug and vaccine testing. Here, we transiently transduced a replication-defective adenovirus encoding hACE2 into the lungs of commercially available mice, which sensitized them to productive SARS-CoV-2 infection and pneumonia. In addition to creating an accessible model for studying SARS-CoV-2 pathogenesis in the lung, we established that systemic delivery of a neutralizing monoclonal antibody mitigates viral infection, inflammation, and disease.

Results and Discussion {#sec2}
======================

Based on prior studies with the closely related SARS-CoV betacoronavirus ([@bib17]), we initially hypothesized that SARS-CoV-2 might infect and cause limited disease in immunocompromised laboratory strains of mice. To test this idea, we propagated SARS-CoV-2 (strain 2019n-CoV/USA_WA1/2020) in Vero CCL-81 cells and inoculated 3-to-4-week-old BALB/c, DBA/2J, *Stat1* ^−/−^ C57BL/6, AG129 (type I and II interferon \[IFN\] receptor-deficient), and *Rag1* ^−/−^ C57BL/6 (no mature B and T cells) mice with 10^5^ focus-forming units (FFUs) of SARS-CoV-2 via an intranasal route. None of the mice tested had weight loss over the first week, and lungs harvested at 10 days post-infection (dpi) showed very low levels of viral RNA ([Figures 1](#fig1){ref-type="fig"}A and 1B). The observation that SARS-CoV-2 does not replicate efficiently in laboratory strains of mice is similar to that seen with MERS-CoV ([@bib7]), which was because of an inability to use the murine ortholog of the MERS-CoV receptor, dipeptidyl peptidase 4 (DPP4) ([@bib36]). Given that human but not mouse ACE2 can act as a cellular receptor for SARS-CoV-2 *in vitro* ([@bib16], [@bib24], [@bib44]), our findings in conventional laboratory mice were anticipated and indeed recently reported by others ([@bib3]).Figure 1SARS-CoV-2 Infection in Conventional Laboratory Strains of Mice and Expression of hACE2 after AdV Transduction(A and B) 3-to-4-week-old BALB/c, DBA/2J, *Stat1*^−/−^ C57BL/6, *Rag1*^−/−^ C57BL/6, and AG129 mice were inoculated via combined intranasal and intravenous routes with 10^5^ focus-forming units (FFU) of SARS-CoV-2. Weight change (A) was monitored, and viral burden (B) in the lung was determined at 10 dpi by RT-qPCR and expressed as copies of viral N gene per mg of tissue (n = 2 to 3 for each strain). Naive mice are shown as a control. Error bars indicate standard deviations (SD).(C) HEK293 cells were transduced with AdV-hACE2-GFP. Flow cytometric analysis of hACE2 and GFP expression was analyzed at 4 and 10 h after AdV transduction. One of two experiments is shown.(D) mRNA expression levels of hACE2 in the lungs of mice receiving the AdV-hACE2 at D-3, D-1, D0, and D4 relative to SARS-CoV-2 infection (2, 4, 5, and 8 days after AdV delivery) via intranasal route as measured by species-specific qRT-PCR of hACE2. Bars indicate median values.(E) *In situ* hybridization using probes for hACE2 in lungs of control mice receiving anti-Ifnar1 mAb (left) or at D-3, D-1, and D0 relative to SARS-CoV-2 infection (2, 4, or 5 days post-transduction of mice receiving anti-Ifnar1 + AdV-hACE2) (right). Images show low-power (top; scale bars, 100 μm) and medium-power (middle \[blue\] and bottom \[red\]; scale bars, 100 μm) magnifications with an additional high-power magnification inset (scale bars, 10 μm). Arrows indicate hACE2-positive cells in medium-power magnification (representative images from n = 3 per group).

Mice transgenic for the expression of hACE2 are vulnerable to SARS-CoV, with infection of lungs observed after intranasal inoculation ([@bib28], [@bib29]). However, SARS-CoV also enters the brain in these hACE2-transgenic mice, and infection results in transneuronal spread and ultimately death due to central nervous system injury and dysfunction ([@bib29], [@bib32]). Because these hACE2-Tg mice are not yet widely available for drug and vaccine testing, we evaluated an alternative strategy in which hACE2 is transiently expressed following transduction with an adenoviral vector, akin to an approach that rendered mice susceptible to MERS-CoV infection by introducing DPP4 ([@bib48]). 9-week-old BALB/c mice were inoculated via an intranasal route with 2.5 × 10^8^ plaque-forming units (PFUs) of a replication-defective adenovirus encoding for hACE2 (hACE2-expressing human Ad5, AdV-hACE2) ([Figure 1](#fig1){ref-type="fig"}C). Some of the animals received an anti-Ifnar1 monoclonal antibody (mAb MAR1-5A3, 2 mg via intraperitoneal injection) to transiently inhibit type I IFN signaling and possibly enhance SARS-CoV-2 infection. We detected hACE2 mRNA by qRT-PCR ([Figure 1](#fig1){ref-type="fig"}D) and by *in situ* hybridization in cells of the lungs including bronchiolar epithelial cells and pneumocytes ([Figure 1](#fig1){ref-type="fig"}E) with peak mRNA expression occurring about five days after administration.

In an attempt to maximize infectivity and pathogenesis, BALB/c mice were inoculated initially via intranasal and intravenous routes with 10^5^ FFUs of SARS-CoV-2 5 days after AdV-hACE2 transduction ([Figure 2](#fig2){ref-type="fig"} A). In contrast to mice transduced only with AdV-hACE2, animals administered AdV-hACE2 and inoculated with SARS-CoV-2 had weight loss during the first week (10%--25%, [Figure 2](#fig2){ref-type="fig"}B). More weight loss was observed in the SARS-CoV-2-infected mice that also received anti-Ifnar1 mAb treatment. High levels of SARS-CoV-2 infectious virus (by plaque assay) and viral RNA were detected in lung tissue homogenates at 4 dpi, whereas lower levels were present in other tissues (e.g., heart, spleen, and brain) and virtually none was measured in kidney, gastrointestinal tract tissues, or in serum ([Figures 2](#fig2){ref-type="fig"}C and 2D). These differences in tissue distribution of SARS-CoV-2 infection likely relate both to the delivery and expression of the AdV-hACE2 and the natural tropism of the virus. Virus inoculation by a systemic route was not required, as we did not observe substantive differences in lung infection when SARS-CoV-2 was administered via intranasal only versus combined intranasal and intravenous routes ([Figure 2](#fig2){ref-type="fig"}E).Figure 2SARS-CoV-2 Infection in AdV-hACE2-Transduced Mice(A) 8-to-10-week-old male and female BALB/c mice received anti-Ifnar1 mAb (2 mg, intraperitoneal \[i.p.\] route; day −5), hACE2-AdV (2.5 × 10^8^ PFU, intranasal \[i.n.\] route, day −5), or SARS-CoV-2 (10^5^ FFU, i.n. + intravenous \[i.v.\] route, day 0) as indicated.(B and C) Weight change was monitored (B) and viral burden in the lungs was analyzed at 4 dpi by plaque assay (C) (two experiments). Error bars indicate SD. The dashed line indicates the assay limit of detection.(D--H) Viral RNA levels in tissues of BALB/c (D--F and H) or C57BL/6J (G) mice after AdV-hACE2 transduction (i.n.) and SARS-CoV-2 inoculation (i.n. only, E--G; i.n. + i.v., D--E and H, route) was measured by RT-qPCR after harvesting at indicated days. As indicated in each graph legend, in some experiments anti-Ifnar1 mAb was administered prior to hACE2-AdV transduction and/or SARS-CoV-2 inoculation. All symbols are color-coded to the indicated experimental conditional and represent data from individual mice. (E--H) Bars indicate median values.(I) SARS-CoV-2 RNA *in situ* hybridization of lungs of naive mice or mice receiving AdV-hACE2 only, AdV-hACE2 + SARS-CoV-2, AdV-hACE2 + anti-Ifnar1 mAb + SARS-CoV-2 at 4 dpi. Images show low- (top; scale bars, 100 μm) and medium- (middle; scale bars, 100 μm) power magnification with a high-power magnification inset (scale bars, 10 μm; representative images from n = 3 per group).

To define the kinetics of infection, we monitored SARS-CoV-2 levels over time in AdV-hACE2-transduced and non-transduced mice after intranasal inoculation. While high and sustained levels of viral RNA were observed at early time points (days 1, 2, and 4) in AdV-hACE2-transduced, SARS-CoV-2-infected BALB/c and C57BL/6J mice, the input viral RNA rapidly decreased in animals receiving only SARS-CoV-2 in the absence of AdV-hACE2 ([Figures 2](#fig2){ref-type="fig"}F and 2G), consistent with the idea that hACE2 is required for robust productive infection. Although viral RNA levels waned by days 8 and 10 dpi (∼1,000-fold reduction), they were still readily detected in all cohorts of AdV-hACE2-transduced, SARS-CoV-2-infected mice ([Figure 2](#fig2){ref-type="fig"}H). The high levels of SARS-CoV-2 infection in the lung of AdV-hACE2 transduced mice at 4 dpi were confirmed by viral RNA *in situ* hybridization, with prominent staining observed in epithelial cells lining the bronchioles and alveoli ([Figure 2](#fig2){ref-type="fig"}I). Even in the absence of anti-Ifnar1 mAb treatment, SARS-CoV-2 RNA was readily detected in lung sections.

We evaluated the impact of SARS-CoV-2 infection on lung histopathology after staining with hematoxylin and eosin (H&E). At 4 dpi, mice transduced with recombinant AdV-hACE2 alone showed mild immune cell infiltration in peribronchiolar, perivascular, and alveolar sites compared with untreated mice ([Figures 3](#fig3){ref-type="fig"}A and 3B). At this early time point, these changes were similar in mice also infected with SARS-CoV-2 with or without additional treatment with anti-Ifnar1 antibody ([Figure 3](#fig3){ref-type="fig"}B). By 8 dpi, mice given AdV-hACE2 alone showed only focal perivascular inflammation that varied little from the untreated control mice ([Figure 3](#fig3){ref-type="fig"}C). However, at this later time point, AdV-hACE2-transduced, SARS-CoV-2-infected mice showed a substantial increase in immune cell infiltration featuring neutrophil accumulation in perivascular and alveolar locations and vascular congestion ([Figure 3](#fig3){ref-type="fig"}C). Moreover, AdV-hACE2-transduced, SARS-CoV-2-infected mice given anti-Ifnar1 mAb showed disease progression with a marked increase in immune cell infiltration in perivascular and alveolar sites along with parenchymal fluid, fibrin, and macrophage accumulation ([Figure 3](#fig3){ref-type="fig"}C). The findings seen after SARS-CoV-2 infection at 8 dpi are consistent with severe viral pneumonia found at autopsy in non-human primates with experimental SARS-CoV-2 infection ([@bib31]) and humans with COVID-19 ([@bib4], [@bib26]). Collectively, these studies establish that administration of an AdV encoding the hACE2 receptor to commercially available mice renders them susceptible to SARS-CoV-2 lung infection, clinical disease, and pathology.Figure 3Histopathological Analysis of SARS-CoV-2 Infection in AdV-hACE2-Transduced BALB/c Mice(A--C) Hematoxylin and eosin staining of lung sections from BALB/c mice after no treatment (A) or after intranasal administration of AdV-hACE2, AdV-hACE2 + SARS-CoV-2, or AdV-hACE2 + anti-Ifnar1 Ab + SARS-CoV-2 with tissue analysis at 4 dpi (B) or 8 dpi (C) using the protocol described in [Figure 2](#fig2){ref-type="fig"}. Scale bars, 500 μm. Each image is representative of a group of 3 mice.

To assess the utility of this model for evaluating possible therapeutics, we passively transferred to anti-Ifnar1-antibody treated, AdV-hACE2-transduced BALB/c mice a single dose (10 mg/kg) of an anti-SARS-CoV-2 mAb 1B07 or isotype control mAb 1 day before intranasal SARS-CoV-2 inoculation ([Figure 4](#fig4){ref-type="fig"} A). The 1B07 mAb is a chimeric mouse Fv-human Fc (IgG1) antibody that was generated after immunization of C57BL/6J mice with SARS-CoV-2 S protein, single B cell sorting with purified receptor-binding domain (RBD) and direct cloning and expression; this mAb recognizes the SARS-CoV-2 RBD as determined by ELISA (A. Ellebedy, unpublished data). 1B07 potently neutralized SARS-CoV-2 infection in Vero cells with an EC~50~ of 37 ng/mL whereas another anti-SARS-CoV-2 mAb (2F05) that recognized the viral S protein lacked inhibitory activity ([Figure 4](#fig4){ref-type="fig"}B). Prophylaxis with 1B07 prevented SARS-CoV-2-induced weight loss through the first 4 days of infection ([Figure 4](#fig4){ref-type="fig"}C) and markedly reduced infectious virus and viral RNA levels in the lung as determined by plaque assay, qRT-PCR assay, and viral RNA *in situ* hybridization ([Figures 4](#fig4){ref-type="fig"}D--4E and [5](#fig5){ref-type="fig"}A). We also observed lower levels of SARS-CoV-2 RNA at distant tissue sites (e.g., heart and spleen) ([Figures 4](#fig4){ref-type="fig"}F and 4G). Finally, at 4 dpi, lower levels of several pro-inflammatory cytokines and chemokines (*IL-6*, *CCL2*, *CCL5*, *CXCL10*, *CXCL11*, *IFN-λ*, and *IFN-β*) were detected in bulk lung homogenates from mice treated with 1B07 compared with the isotype control mAb ([Figure 4](#fig4){ref-type="fig"}H), and this phenotype correlated with decreased immune cell infiltrates in the lungs at 6 dpi in animals treated with 1B07 ([Figure 5](#fig5){ref-type="fig"}B). These data suggest that neutralizing antibodies can protect against SARS-CoV-2-induced lung inflammation.Figure 4Protective Effect of a Neutralizing mAb against SARS-CoV-2 Infection(A) Experimental scheme. 8-week-old male BALB/c mice were treated with anti-Ifnar1 mAb and transduced with AdV-hACE2 via the i.n. route. Four days later, mice were treated via i.p. route with 200 ug of 1B07 (anti-SARS-CoV-2) or isotype control 2H09 (anti-influenza A virus) mAb. One day later, SARS-CoV-2 (4 × 10^5^ FFU per mouse) was inoculated via an i.n. route.(B) Anti-SARS-CoV-2 mAbs (1B07 and 2F05) were incubated with 10^2^ FFU of SARS-CoV-2 for 1 h at 37°C followed by addition of mAb-virus mixture to Vero E6 cells. Virally infected foci were stained and counted. Wells containing mAb were compared with wells containing no mAb to determine the relative infection. One experiment of three is shown.(C--G) *In vivo* outcomes. Weight change (C) was monitored (n = 15--16, two-way ANOVA with Sidak's post-test: ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001), and viral burden at 4 dpi was determined in the lung (D and E), heart (F), and spleen (G) by plaque assay (D) or qRT-PCR (E--G) (D, n = 6; E--G, n = 13--16; Mann-Whitney test, ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗∗^p \< 0.0001). The dashed line indicates the assay limit of detection.(H) Fold change in gene expression of indicated cytokines and chemokines was determined by qRT-PCR, normalized to *Gapdh,* and compared with naive controls in lung homogenates at 4 dpi from 1B07 or isotype control mAb-treated mice (three experiments, n = 13-15 per group, Mann-Whitney test: ns, not significant, ^∗^p \< 0.05, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001). Dotted line indicates the average level of cytokine or chemokine transcript in naive mice. Error bars indicate standard error of the mean (C), and bars represent median values (D--H).Figure 5Pathological Analysis of SARS-CoV-2 Infection in Anti-SARS-CoV-2-mAb-Treated AdV-hACE2-Transduced BALB/c Mice(A) SARS-CoV-2 RNA *in situ* hybridization at 4 dpi of lungs from 8-week-old BALB/c mice treated with 200 μg of 1B07 (anti-SARS-CoV-2) or isotype control 2H09 (anti-influenza A virus) that also received AdV-hACE2 + anti-Ifnar1 mAb + SARS-CoV-2 as described in [Figure 4](#fig4){ref-type="fig"}. Images show low- (top; scale bars, 100 μm) and medium- (middle; scale bars, 100 μm) power magnification with a high-power magnification inset (scale bars, 10 μm; representative images from n = 3 per group).(B) Hematoxylin and eosin staining of lung sections from 8-week-old BALB/c mice at 6 dpi after treatment with 1B07 or isotype control mAbs. Mice were given an intranasal administration of AdV-hACE2 + anti-Ifnar1 Ab + SARS-CoV-2 as described in [Figure 4](#fig4){ref-type="fig"}. Images show low- (left; scale bars, 250 μm), medium- (middle; scale bars, 50 μm), and high-power magnification (scale bars, 25 μm). Each image is representative of a group of 3 mice.

In summary, we have developed a model of SARS-CoV-2 lung infection and disease in commonly available laboratory mice by rapidly sensitizing them via an intranasal delivery of replication-defective AdV encoding the hACE2 receptor. Although transient type I IFN blockade was not necessary or sufficient for SARS-CoV-2 infection in mice, we observed greater weight loss and lung pathology in the absence of intact IFN signaling. The basis for this remains uncertain but could be because of a lack of IFN-induced epithelial cell repair ([@bib42]), sustained signaling of alternate pro-inflammatory pathways in the absence of IFN ([@bib35]), or a deficiency of protective IFN-λ responses in the lung ([@bib13], [@bib21]) because IFN-λ itself is an IFN-stimulated gene ([@bib22]). Studies are planned to determine whether specific IFN subtypes mediate this protective effect against SARS-CoV-2 pathogenesis, as IFN-α and IFN-β can have disparate antiviral and immunomodulatory effects ([@bib8], [@bib33]).

Further model refinement is planned using additional laboratory mouse strains ([@bib5]), animals of different ages and sex, and mice with distinct underlying comorbidities (e.g., diabetes or obesity) that are risk factors for severe COVID-19 in humans ([@bib49]). Moreover, this AdV-hACE2 transduction system could be used immediately in the context of Collaborative Cross mice ([@bib34]) or the large library of genetic knockout mice in academic, governmental, and commercial laboratories to identify host susceptibility and restriction factors for SARS-CoV-2 infection. Consistent with our studies, a separate group has analogously transduced hACE2 into C57BL/6 and BALB/c mice and successfully generated a SARS-CoV-2 pathogenesis model of lung infection and disease ([@bib41]).

Limitations of Study {#sec2.1}
--------------------

Our model has some limitations compared with fully transgenic hACE2 mice ([@bib3], [@bib28], [@bib29]) or other small animal models (e.g., hamsters and ferrets) of SARS-CoV-2 infection that are in development ([@bib6], [@bib20], [@bib40]). These include potential mouse-to-mouse variation in hACE2 expression and tissue distribution and mild bronchial inflammation associated with AdV delivery. Notwithstanding these caveats, we consistently observed high levels of lung infection and pneumonia in our dual AdV-hACE2-transduced and SARS-CoV-2-infected mice. Moreover, viral infection and several inflammatory mediators in the SARS-CoV-2-infected lung were reduced by neutralizing antibody treatment. Of note, IL-6 levels in the lung were decreased after treatment with 1B07 anti-S protein mAb. In non-randomized trials in COVID-19 patients, treatment with tocilizumab, an IL-6 inhibitor, preliminarily was associated with less inflammation and clinical improvement ([@bib1], [@bib14]). Our mouse model provides definitive evidence that antibody-based treatments can mitigate SARS-CoV-2 infection *in vivo*, analogous to that described for SARS-CoV and MERS-CoV infections ([@bib9], [@bib43]), and suggests a path forward for identifying therapeutic antibody candidates or combinations with even greater potency and protective activity. The availability of SARS-CoV-2 small animal models that are easily generated with commercially available mice can accelerate the pace of screening, identification, and development of countermeasures (drugs, vaccines, and antibody therapeutics) for advancement to pivotal non-human primate and human studies.

STAR★Methods {#sec3}
============

Key Resources Table {#sec3.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**1B07, anti-SARS-CoV-2 mAbThis paperN/A2F05, anti-SARS-CoV-2 mAbThis paperN/A2H09, anti-influenza A virus mAbThis paperN/AGoat anti-human ACE2 antibodyR&DAF933; RRID: [AB_355722](nif-antibody:AB_355722){#intref0015}APC-conjugated donkey anti-goat IgG secondary antibodyThermo FisherA32849; RRID: [AB_2762840](nif-antibody:AB_2762840){#intref0020}CR3022, anti-SARS-CoV-2 mAb[@bib47]N/AHRP-conjugated goat anti-human IgGThermo Fisher62-8420; RRID: [AB_2533962](nif-antibody:AB_2533962){#intref0025}MAR1-5A3, anti-Ifnar1 mAbLeincoI-401;\
RRID: [AB_2491621](nif-antibody:AB_2491621){#intref0030}**Virus Strains**SARS-CoV-2 (strain 2019 n-CoV/USA_WA1/2020)CDC/BEI ResourcesNR52281AdV-hACE2-GFP[@bib18]N/AAdV-hACE2[@bib18]N/A**Experimental Models: Cell Lines**Vero CCL-81ATCCCCL-81; RRID: CVCL_0059Vero E6ATCCCRL-1586; RRID: CVCL_0574HEK293ATCCCRL-1573; RRID: CVCL_0045HEK293TATCCCRL-3216; RRID: CVCL_0063**Experimental Models: Organisms/Strains**Mouse: C57BL/6JJackson LaboratoryCat\#000664; RRID: IMSR_JAX:000664Mouse: BALB/cJackson LaboratoryCat\#000651; RRID: IMSR_JAX:000651Mouse: DBA/2JJackson LaboratoryCat\#000671; RRID: IMSR_JAX:000671Mouse: Rag1^−/−^ C57BL/6Jackson LaboratoryCat\#002216; RRID: IMSR_JAX:002216Mouse: Stat1^−/−^ C57BL/6Jackson LaboratoryCat\#012606; RRID: IMSR_JAX:012606AG129Marshall BioResourcesAG129**Oligonucleotides**SARS-CoV-2 N **F**: 5′-ATGCTGCAATCGTGCTACAA-3′This paperN/ASARS-CoV-2 N **R**: 5′-GACTGCCGCCTCTGCTC-3′This paperN/ASARS-CoV-2 N **Probe**: 5′-/56-FAM/TCAAGGAAC/ZEN/AACATTGCCAA/3IABkFQ/-3′This paperN/ASARS-CoV-2 RNA ISH probe (S gene)Advanced Cell DiagnosticsCat\# 4848561Human ACE2 RNA ISH probeAdvanced Cell DiagnosticsCat\# 848151*Gapdh* TaqMan Primer/Probe setIDTMm.PT.39a.1Human *ACE2* TaqMan Primer/Probe setIDTHs.PT.58.27645939*Ifng* TaqMan Primer/Probe setIDTMm.PT.58.41769240*Il6* TaqMan Primer/Probe setIDTMm.PT.58.10005566*Il1b* TaqMan Primer/Probe setIDTMm.PT.58.41616450*Tnfa* TaqMan Primer/Probe setIDTMm.PT.58.12575861*Cxcl10* TaqMan Primer/Probe setIDTMm.PT.58.43575827*Ccl2* TaqMan Primer/Probe setIDTMm.PT.58.42151692*Ccl5* TaqMan Primer/Probe setIDTMm.PT.58.43548565*Cxcl11* TaqMan Primer/Probe setIDTMm.PT.58.10773148.g*Ifnb* TaqMan Primer/Probe setIDTMm.PT.58.30132453.g*Ifnl*(2/3*)* TaqMan Primer/Probe setThermo FisherMm04204156_gH**Software and Algorithms**BioRender[BioRender.com](http://BioRender.com){#interref0010}N/AFlowJoFlowJo, LLCv10GraphPad PrismGraphPadv 8.2.1**Recombinant DNA**pABVec6W[@bib10]N/APCR-II topoInvitrogenCat\# 451245

Resource Availablity {#sec3.2}
--------------------

### Lead Contact {#sec3.2.1}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Michael S. Diamond (<diamond@wusm.wustl.edu>).

### Materials Availability {#sec3.2.2}

All requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact author. This includes transgenic mice, antibodies, viruses, and proteins. All reagents will be made available on request after completion of a Materials Transfer Agreement.

### Data and Code Availability {#sec3.2.3}

All data supporting the findings of this study are available within the paper and are available from the corresponding author upon request.

Experimental Model and Subject Details {#sec3.3}
--------------------------------------

### Cells and viruses {#sec3.3.1}

Vero E6 (CRL-1586, American Type Culture Collection (ATCC), Vero CCL81 (ATCC), HEK293 (ATCC), and HEK293T (ATCC) were cultured at 37°C in Dulbecco's Modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 10 mM HEPES pH 7.3, 1 mM sodium pyruvate, 1 × non-essential amino acids, and 100 U/mL of penicillin--streptomycin.

SARS-CoV-2 strain 2019 n-CoV/USA_WA1/2020 was obtained from the Centers for Disease Control and Prevention (gift of Natalie Thornburg). Virus was passaged in Vero CCL81 cells and titrated by focus-forming assay on Vero E6 cells. All work with infectious SARS-CoV-2 was performed in Institutional Biosafety Committee approved BSL3 and A-BSL3 facilities at Washington University School of Medicine using appropriate positive pressure air respirators and protective equipment.

### Monoclonal antibodies {#sec3.3.2}

1B07 and 2F05 are chimeric mouse Fv-human Fc (IgG1) mAbs that were generated after immunization of C57BL/6J mice with SARS-CoV-2 S protein, single B cell sorting and direct cloning into pABVec6W vectors ([@bib10]). After transfection and expression in 293F cells, 1B07, 2F05, and a control anti-influenza A mAb (2H09) were purified by protein A chromatography.

### Adenoviruses {#sec3.3.3}

The AdV-hACE2-GFP and AdV-hACE2 constructs and defective virus preparation was reported previously ([@bib18]) and prepared initially by the University of Iowa Viral Vector Core and separately at Washington University. AdV-hACE2-GFP and AdV-hACE2 were propagated in 293T cells and purified using cesium chloride density-gradient ultracentrifugation, and the number of virus particles was determined using optical density (260 nm) measurement and plaque assay, as previously described ([@bib30]).

### Mouse experiments {#sec3.3.4}

Animal studies were carried out in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocols were approved by the Institutional Animal Care and Use Committee at the Washington University School of Medicine (assurance number A3381--01). Virus inoculations were performed under anesthesia that was induced and maintained with ketamine hydrochloride and xylazine, and all efforts were made to minimize animal suffering.

Mice were purchased from commercial vendors (BALB/c, C57BL/6J, and DBA2/J, Jackson Laboratories) or propagated at Washington University School of Medicine (*Stat1* ^−/−^ C57BL/6; *Rag1* ^−/−^ C57BL/6, and AG129). Animals were housed in groups and and fed standard chow diets. Mice of different ages and both sexes (three to four or eight to ten week-old, indicated in each Figure legend) were administered 2.5 × 10^8^ PFU of AdV-hACE2 via intranasal administration. In some experiments, an intraperitoneal injection of 2 mg of anti-Ifnar1 mAb (MAR1-5A3 ([@bib39]), Leinco) was given before (−24 h) or after (+ 4 days) AdV-hACE2 treatment. Five days after AdV transduction, mice were inoculated with SARS-CoV-2 via intranasal only or both intranasal and intravenous routes. Weights were monitored on a daily basis, and animals were sacrificed at 1, 2, 4, 8, or 10 dpi and tissues were harvested. 1B07 or isotype control 2H09-treated mice were euthanized and perfused with 20 mL of PBS after serum collection via cardiac puncture and before tissue harvest.

Method Details {#sec3.4}
--------------

### Flow cytometry {#sec3.4.1}

HEK293 were transduced with AdV-hACE2-GFP. Cells were detached and stained with a primary human ACE2 antibody (R&D, 1:200) in PBS, 2% FBS, and 5% donkey serum for 1 h at 4°C and then stained with an APC-conjugated donkey anti-goat secondary antibody (Thermo Fisher, 1:1000) for 30 min at 4°C. Data was collected on a MACSQuant X Flow cytometer and analyzed using FlowJo V10.

### Measurement of viral burden and *hACE2* expression {#sec3.4.2}

Tissues were weighed and homogenized with zirconia beads in a MagNA Lyser instrument (Roche Life Science) in 1000 μL of DMEM media supplemented with 2% heat-inactivated FBS. Tissue homogenates were clarified by centrifugation at 10,000 rpm for 5 min and stored at −80°C. RNA was extracted using MagMax mirVana Total RNA isolation kit (Thermo Scientific) and a Kingfisher duo prime extraction machine (Thermo Scientific). For some samples, viral burden was determined by plaque assays on Vero E6 cells.

To identify highly conserved regions within coronaviruses, the originally published nucleotide sequence of SARS-CoV-2 (GenBank MN908947) was aligned with two related bat SARS-like CoV (GenBank MG772933.1 and MG772934.1) using MUSCLE ([@bib12]). We identified a ∼100 base pair nucleotide region in the nucleocapsid (N) gene coding sequence that had 100% sequence identity between the aligned coronaviruses. Primers were designed to target this conserved region using SARS-CoV-2 (MN908947) sequence as a guide (L Primer: ATGCTGCAATCGTGCTACAA; R primer: GACTGCCGCCTCTGCTC; probe: /56-FAM/TCAAGGAAC/ZEN/AACATTGCCAA/3IABkFQ/). To establish an RNA standard curve, we generated concatenated segments of the N gene in a gBlocks fragment (IDT) and cloned this into the PCR-II topo vector (Invitrogen). The vector was linearized and *in vitro* T7-DNA-dependent RNA transcription performed to generate materials for a quantitative standard curve. When used in combination with our generated primer-probe set and a known amount of the plasmid control, N gene copy-numbers could be determined down to 10 copies per reaction.

For *hACE2* expression, RNA was DNase-treated (Thermo Scientific) following the manufacturer's protocol. RNA levels were quantified as described above with the primer/probe set for *hACE2* (IDT assay: Hs.PT.58.27645939), compared to an RNA standard curve, and normalized to mg of tissue.

### Cytokine and chemokine mRNA measurements {#sec3.4.3}

RNA was isolated from lung homogenates as described above. cDNA was synthesized from DNase-treated RNA using the High-Capacity cDNA Reverse Transcription kit (Thermo Scientific) with the addition of RNase inhibitor following the manufacturer's protocol. Cytokine and chemokine expression was determined using TaqMan Fast Universal PCR master mix (Thermo Scientific) with commercial primers/probe sets specific for *IFN-γ* (IDT: Mm.PT.58.41769240), *IL-6* (Mm.PT.58.10005566), *IL-1β* (Mm.PT.58.41616450), *TNF-α* (Mm.PT.58.12575861), *CXCL10* (Mm.PT.58.43575827), *CCL2* (Mm.PT.58.42151692), *CCL5* (Mm.PT.58.43548565), *CXCL11* (Mm.PT.58.10773148.g), *IFN-β* (Mm.PT.58.30132453.g), and *IFNλ−2/3* (Thermo Scientific Mm04204156_gH) and results were normalized to *GAPDH* (Mm.PT.39a.1) levels. Fold change was determined using the 2^-ΔΔCt^ method comparing treated mice to naive controls.

### Histology and RNA *in situ* hybridization {#sec3.4.4}

Animals were euthanized, and tissues were harvested before lung inflation and fixation. The left lung was tied off at the left main bronchus and collected for viral RNA analysis. The right lung was inflated with ∼1.2 mL of 10% neutral buffered formalin using a 3-mL syringe and catheter inserted into the trachea. For fixation after infection, inflated lungs were kept in a 40-mL suspension of neutral buffered formalin for 7 days before further processing. Tissues were embedded in paraffin, and sections were stained with hematoxylin and eosin. RNA *in situ* hybridization was performed using the RNAscope 2.5 HD Assay (Brown Kit) according to the manufacturer's instructions (Advanced Cell Diagnostics). Briefly, sections were deparaffinized, treated with H~2~O~2~ and Protease Plus prior to probe hybridization. Probes specifically targeting hACE2 (cat no. 848151) or SARS-CoV-2 S sequence (cat no 848561) were hybridized followed by proprietary signal amplification and detection with 3,3′-Diaminobenzidine. Tissues were counterstained with Gill's hematoxylin. An uninfected mouse was used as a negative control and stained in parallel. Tissue sections were visualized using a Nikon Eclipse microscope equipped with an Olympus DP71 color camera or a Leica DM6B microscope equipped with a Leica DFC7000T camera.

### Neutralization assay {#sec3.4.5}

Serial dilutions of mAbs 1B07 or 2F05 were incubated with 10^2^ focus-forming units (FFU) of SARS-CoV-2 for 1 h at 37°C. mAb-virus complexes were added to Vero E6 cell monolayers in 96-well plates and incubated at 37°C for 1 h. Subsequently, cells were overlaid with 1% (w/v) methylcellulose in MEM supplemented with 2% FBS. Plates were harvested 30 h later by removing overlays and fixed with 4% PFA in PBS for 20 min at room temperature. Plates were washed and sequentially incubated with 1 μg/mL of CR3022 ([@bib47]) anti-S antibody and HRP-conjugated goat anti-human IgG in PBS supplemented with 0.1% saponin and 0.1% bovine serum albumin. SARS-CoV-2-infected cell foci were visualized using TrueBlue peroxidase substrate (KPL) and quantitated on an ImmunoSpot microanalyzer (Cellular Technologies). Data were processed using Prism software (GraphPad Prism 8.0).

Quantification and Statistical Analysis {#sec3.5}
---------------------------------------

Statistical significance was assigned when *P value*s were \< 0.05 using Prism Version 8 (GraphPad) and are indicated in the relevant Figure legends. Analysis of weight change and viral burden *in vivo* were determined by two-way ANOVA and Mann-Whitney tests, respectively.
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